Novo Nordisk Announces Ziltivekimab Did Not Translate Into Major Adverse Cardiovascular Events Risk Reduction During Phase 3 Trial In Patients With Atherosclerotic Cardiovascular Disease
Novo Nordisk today announced headline results from the ZEUS cardiovascular outcomes phase 3 trial.While ziltivekimab demonstrated target engagement and inhibition of the IL-6 pathway, as reflected by expected reductions
Novo Nordisk tested a new medicine to help heart patients, but it didn't work as well as hoped—the medicine reached its target in the body, but didn't reduce serious heart problems enough. When a medicine doesn't meet its main goal in a big test, that's important to know because it shows which treatments might not help patients the way doctors thought.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.